# Effects of statins on delaying progression of chronic kidney disease: a meta-analysis

LIU Zongrui', ZHAO Hao', CHEN Yanrong², TANG Dongdong',and NIU Hongxin1,\* 'Departmentofologyupatinteprnt,ngHspital,uicalUesitygu

Abstract:Objective Whether statins can slow down theprogresionof chronic kidney disease (CKD)remainscontroversial. We performed a meta-analysis toevaluatetheeffects ofstatintherapyondisease progresion inadult patients withCKD who did not equire dialysis therapy. Methods We searched the electronic databases forrelevant randomized controlld trials (RCTs)published byFebruary2015.Random-effects meta-analysisof RCTs was used topooltherenal outcomesof the patients.Results Twenty-eight studies (30RCTs)involving a total of 45 688participants were included intheanalysis. Compared with thecontrol groups,statins produced no effects in preventing end-stage renal disease (ESRD)[relative risks (RR) 0.98, $9 5 \%$ confidence intervals (CI): 0.91-1.05] and in reducing the risk of doubling of the serum creatinine level (RR 1.43, $9 5 \%$ CI: 0.26-7.79).Statin therapy was asociated witha lowered risk of estimated glomerular filtration rate (eGFR)reduction by $2 5 \%$ or more (RR 0.91, $9 5 \%$ CI: 0.83-0.99) and delayed the reduction of eGFR [standardized mean differences (SMD) 0.04, $9 5 \%$ CI: 0.02-0.07]. In subgroupanalyses,the benefit of statins onchanges in eGFR wasstatisticallysignificant in patients with moderate CKD( $\operatorname { S M D } \ 0 . 0 9 ,$ $9 5 \%$ CI 0.04-0.13). Among different statins,atorvastatin was associated with a beneficial effect on kidney function (SMD 0.10, $9 5 \%$ CI 0.03-0.17). Patients who received high-intensity statin therapy showed significant changes in eGFR (SMD 0.12, $9 5 \%$ CI: 0.02-0.21). Conclusion Statin therapies may not prevent ESRD or doubling of serum creatinine level,butcan improve GFRordelaythereductionof GFRinCKDpatients.Thetherapeuticeffectsareassciated with the patients' baseline eGFR levels, statin types and therapy intensity.

Key words: statins; chronic kidney disease; end-stage renal disease; glomerular filtration rate; meta-analysis

# INTRODUCTION

Chronic kidney disease (CKD) is associated with an increased risk of mortality,cardiovascular events, hospitalizationandincreasedhealthcarecosts[1-3]. Patients with CKD often have dyslipidemia[46],which plays an important role in the progression of kidney disease [6-8] Statins，inhibitorsof3-hydroxy-3- methylglutaryl CoA reductase that is essentialfor cholesterol synthesis,are not widely used in patients with CKD[5]. Accumulating evidence from a variety of animal models suggests a role of statins in delaying the progression of kidney disease[9-12], which is attributed to theirpleiotropiceffectsindependentoftheir lipid-lowering effects[9,13-i5]. But so far the effect of statins ontheprogression of CKD remainscontroversial. Previous meta-analyses of randomized trials indicated that statin therapy modestly reduced proteinuria and the rate of kidney function loss[16]with a renoprotective effect inCKDpatients [7.i8]。Accordingtoa Cochrane systematic review,statin use can improve cardiovascular outcomes and prevent future cardiovascular events,but have uncertain effects on the progression of kidney disease[i9]TherecentStudyofHeartandRenal Protection (SHARP) trial of a wide range of patients with CKDshowed that lowering low-density lipoprotein cholesterol (LDL-C) with daily simvastatin $( 2 0 ~ \mathrm { m g } )$ plus ezetimibe( $\mathrm { 1 0 ~ \ m g ) }$ did not slow kidneydisease progression within5years 20l Given these divergent data,we performed a meta-analysis to evaluate whether statins can slow kidney disease progression in patients with CKD.

# METHODS

# Data sources and search strategy

WesearchedPubMed,EMBASE,Medline,and the CochraneCentralRegisterofControlledTrials (CENTRAL) for relevant studies published in English by February，2015using following terms:"kidney disease","kidney failure","chronic kidney disease", "CKD","chronicrenalfailure","dyslipidemia", "hypercholesterolemia","hyperlipidemia"，"HMG-CoA reductase inhibitors","HMG-CoA reductase inhibitor" and"statins".Unpublished studies were also searched inthe reference lists of the retrieved articles,in conference proceedings and at https://clinicaltrials.gov/.

# Study selection

We included all the RCTs and quasi-RCTs with a duration of observation for atleast 3 months in adult patients with CKD,including subgroup studies of adult patients with CKD recruited within large-scale statin trials.We also included studies that compared statins with placebo,non-statin treatment and routine care (such as low-fat diet therapy).Studies that compared two different statins,different dose of one satin,or a statin with a non-statin regime (including fibrate therapy) were excluded.We defined CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [21]. Wealso excluded studies that included children with CKD,adult patients on dialysis (peritoneal dialysis or hemodialysis)，and kidney transplant recipients.The outcomes ofinterest were end-stage renal disease (ESRD),doubling of serum creatinine level,a reduction of estimated glomerular filtration rate (eGFR) by over $2 5 \%$ ,and changes of eGFR from the baseline at the end of follow-up.As creatinine clearance is commonly used asan estimate of GFR in spite of their conceptual differences [21] we used creatinineclearance interchangeably with GFR to assess the outcomes of the patients.

# Data extraction and study quality assessment

Two reviewers independently screened the titles and abstracts of the potentially eligible articles，and subsequently reviewed the full texts of these articles. We extracted the data of the study sample,participant characteristics，interventions, and outcomes.Where more than one publication of one study were found, we treated it as one study and combined these reports and extracted the complete data. Any disagreements were resolved by consensus. Two authors independently assessed the risk of bias in the included studies using the risk of bias assessment tool [22] and examined the sequence generation,allocation concealment,blinding of investigators, participants,and outcome assessors, completeness of the outcome data,use of intentionto-treat analysis,selective reporting,and other bias.

# Data synthesis and analysis

Weused relative risk ratios(RR) with $9 5 \%$ confidenceinterval(CI)toassesstheresultsof dichotomous outcomes (ESRD events,doubling of serum creatinine level,and an eGFR reduction by over $2 5 \%$ ） Forcontinuousoutcomes(changesin eGFR from baseline at the end of follow-up)，we calculated the standardized mean differences(SMD) with $9 5 \%$ CI, where different scaleswere used (scales of reported eGFR included mL/min, $\mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \ \mathrm { m } ^ { 2 }$ ，and $\mathrm { m L } / \mathrm { m i n } /$ $1 . 7 3 ~ \mathrm { \ m } ^ { 2 } / \mathrm { y e a r } )$ .When standard deviations (SDs) were unavailable and only the baseline and follow-up eGFR was available, the missing SDs and changes in eGFR from baseline to follow-up were obtained according to the Cochrane Handbook [22].We used the random effects model to pool the data because of the differences among studies,particularly in such clinical characteristics as statintypesand doses, clinicalpopulations, and duration of follow-up.We used the Cochran Q test and $I ^ { 2 }$ test to assess heterogeneity.A $P$ value $< 0 . 0 5$ was considered to indicate a significant difference and $I ^ { 2 }$ values of $2 5 \%$ ， $5 0 \%$ and $7 5 \%$ indicated low,medium and high levels of heterogeneity, respectively[23].

We conducted subgroup analyses to explore the effects of baseline eGFR，statin types,and statin intensity on the renal parameters.We defined mild CKD asa baseline eGFR $\geq 6 0 \ \mathrm { \ m L } / \mathrm { m i n } / 1 . 7 3 \ \mathrm { \ m } ^ { 2 }$ ，moderate CKDasabaseline eGFRof $3 0 { - } 5 9 \ \mathrm { m L } / \mathrm { m i n } / 1 . 7 3 \ \mathrm { m } ^ { 2 }$ ，and severe CKD as a baseline eGFR c $\mathrm { f } { < } 3 0 \mathrm { \ m L } / \mathrm { m i n } / 1 . 7 3 \mathrm { \ m } ^ { 2 }$ The intensity of statin therapy was categorized as high-intensity， moderate-intensity， and low-intensity according to the definitions from the recent American Collegeof Cardiology/AmericanHeart Association guidelines[24].High-intensitystatin therapy wasdefined as one with a therapeutic target of lowering LDL-C by $5 0 \%$ (using atorvastatin at $4 0 { - } 8 0 ~ \mathrm { m g }$ or rosuvastatin at $2 0 – 4 0  { \mathrm { ~ \textrm ~ { ~ ~ } ~ } }  { \mathrm { m g } }$ ，moderate-intensitystatin therapyasa decrease in LDL-C by $30 \%$ to $50 \%$ (using atorvastatin at $1 0 { - } 2 0 ~ \mathrm { ~ m g }$ ，rosuvastatin at $5 { \cdot } 1 0 ~ \mathrm { \ m g }$ ，simvastatin at $2 0 { - } 4 0 ~ \mathrm { m g } .$ ，fluvastatin XL at $8 0 ~ \mathrm { m g }$ ,fluvastatin at $4 0 ~ \mathrm { m g }$ bid,pravastatin at $4 0 { - } 8 0 ~ \mathrm { \ m g }$ ，lovastatin at $4 0 ~ \mathrm { m g }$ or pitavastatin at $2 { \cdot } 4 \ \mathrm { m g } \dot { }$ ),and low-intensity statin therapy aslowering LDL-C by approximately ${ < } 3 0 \%$ (using simvastatin at $1 0 \ \mathrm { \ m g }$ ，fluvastatinat $2 0 – 4 0 \quad \mathrm { m g } .$ pravastatin at $1 0 { - } 2 0 ~ \mathrm { ~ m g }$ ，lovastatinat $2 0 ~ \mathrm { \ m g }$ or pitavastatin at $1 ~ \mathrm { m g } \dot { }$ .A funnel plot was constructed to assesspublicationbias.Sensitivityanalysiswas performed to assess the overall effects of statins by including only those studies that reported blinding of the participants,investigators，and outcome assessors.In additional sensitivity analysis,we excluded studies with a follow-up less than 1 year.

# RUSULTS

# Study selection

Fig.1 shows the flow chart for literature search and selection of articles.We retrieved 129 potentially eligible articles for further assessment,of which 30 RCTs (45 688 participants)of 28 studies[20,251] met our inclusion criteria.Three studies provided data on ESRD, 2studiesprovided data on doubling the serum creatinine level, 4 studies including 6 RCTs (one study including 3 RCTs[34) provided data on an eGFR reduction by over $2 5 \%$ , and 24 studies reported changes in eGFR.The investigated statins included simvastatin (6 studies),pravastatin (8 studies), fluvastatin (3 studies each),atorvastatin (6 studies),cerivastatin(1 study),and lovastatin (1 study).

# Characteristics of included studies and risk of bias

The characteristics of the included studiesare shown in Tab.1. The follow-up ranged from 3 months to 6 years.The mean age of the included participants was 58.4 years and $6 7 . 4 \%$ of the participants were men. The included studies showed a high risk of bias (Fig.2).Of the 28 included studies,8 reported random sequence generation and allocationconcealment, while14 reported blinding participants and personnel, 9 reported blinding outcome assessors,and 1O were considered to have a low risk for incomplete outcome data reporting. Adverse events were reported in 13 studies.The risk of bias due to sources of funding was low in 11 studies.

![](images/e175d1358d1bd20111edbf51e970baf90cb97dce1be87307132b3da26c5c64bf.jpg)  
Fig.1 Flow chart of literature search and selection.

# Effects of statin therapy on progression to ESRD

Three studies of 13 788 participants evaluated the effects of statins on ESRD events (Fig.3).These studies showed no substantial heterogeneity ( $I ^ { 2 } { = } 0$ ， $\scriptstyle P = 0 . 7 8$ ）and reported little or no effect of statins in preventing progression of CKD to ESRD (RR 0.98, $9 5 \%$ CI: 0.91-1.05). We did not perform subgroup analyses because of the small number of studies included.

# Effectsof statins on doubling of serum creatinine level

Two studies of 9512 participants reported that statin therapy showed no beneficial effect on doubling of serum creatinine level (RR 1.43, $9 5 \%$ CI: $0 . 2 6 { = } 7 . 7 9$ Fig.4).Thesetwostudiesshowedamoderate heterogeneity $\scriptstyle { \mathit { I } } ^ { 2 } = 4 6 \%$ ， ${ \it P } { = } 0 . 1 7$ ）and we did not perform subgroup analyses for the small sample size.

# Effectsof statinson eGFR reductionbyover $2 5 \%$

Theresultsof4studies involving $1 7 \quad 0 8 1$ participants showedaprobable beneficial effect of statin therapy on eGFR reduction by over $2 5 \%$ (RR 0.91, $9 5 \%$

CI:0.83-0.99;Fig.5). Thesestudiesshowedno significant heterogeneity $( I ^ { 2 = } 0 , \ P { = } 0 . 4 0 )$ and we did not perform subgroup analyses of these studies.

# Effectsof statinsonchangesofeGFR

Twenty-fourRCTs(includingasubgroup in ALLHAT 2008 and one in MEGA 2009) involving 25 429 participants estimated the effects of statins on changes of eGFR.Overall, the SMD for the effects on eGFR changes was statistically significant (SMD 0.04, $9 5 \%$ CI:0.02-0.07；Fig.6).These RCTshad no heterogeneity $\scriptstyle { I ^ { 2 } = 0 \% }$ ， $\scriptstyle P = 0 . 7 9$ ). To explore the effects of baseline eGFR and statin types on eGFR changes,we conducted a subgroup analysis according to baseline eGFR and statin types.The result showed that the benefit of statin therapy was statistically significant in moderate CKD subgroup of 7491 participants (SMD 0.09, $9 5 \%$ CI: $0 . 0 4 \mathrm { = } 0 . 1 3$ ： $\scriptstyle { I ^ { 2 } = 0 \% }$ ， $P { = } 0 . 9 7$ ； Fig.6). However,statin therapy had no significant effect on eGFR changes in mild (11 693 participants; SMD 0.02, $9 5 \%$ CI: -0.02-0.05; ${ \cal I } ^ { 2 } { = } 0 \%$ ， $P { = } 0 . 5 7$ ）andsevere[only one study (SHARP 2014) of 6 245 participants;SMD 0.04， $9 5 \%$ CI: -0.01-0.09] CKD subgroups. Among these statins,only atorvastatin had a beneficial effect on eGFR changes (SMD 0.10, $9 5 \%$ CI 0.03-0.17) (Fig.7). However,the effects of other statins were not significant [simvastatin:SMD0.05, $9 5 \%$ CI: -0.00-0.10; pravastatin: SMD 0.04, $9 5 \%$ CI: 0.00-0.08; fluvastatin: SMD -0.06, $9 5 \%$ CI: -0.29-0.17; rosuvastatin: SMD 0.13， $9 5 \%$ CI: -O.13 to O.39; cerivastatin (only one study); SMD -0.35, $9 5 \%$ CI: -0.98-0.27l. The benefit of statin therapy on eGFR changeswasstatistically significant instudiesofhigh-intensitystatinas compared with controls (SMD 0.12, $9 5 \%$ CI: 0.02-0.21; Fig.8).No statistically significant difference of eGFR changes was found in patients receiving moderateintensity(SMD0.04, $9 5 \%$ CI:0.00-0.07) or low-intensity (SMD 0.05, $9 5 \%$ CI: -0.01-0.10) therapy. In sensitivity analysis,we found that the results were robust when only those studies reporting blinding techniques were included.Statin therapy still had a favorable effect when trials with follow-up periods $^ { < 1 }$ year were excluded (SMD 0.04, $9 5 \%$ CI: 0.02-0.07).

# Publication bias

There was no asymmetry of the funnel plot regarding eGFR changes, suggesting the absence of publication bias in the included studies (data not shown).Although we planned to examine publication bias of other outcomes using funnel plots,the small number of included studies prohibited this [22].

# DISCUSSION

The findings of this meta-analysis of the 28 studies suggest that statins appeared to have little or no effect on doubling of serum creatinine level and in preventing progression of CKD to ESRD,but can be beneficial to improve GFRorreduce the decline of GFR.

elptt plsrlsrtr selishielaeeettrrel   

<html><body><table><tr><td>Study</td><td>Sample</td><td>Female</td><td></td><td>Statin</td><td>Daymgr</td><td>Foloarup</td><td>Disease</td><td>Baseline mean eGFR</td><td>BTc (inemean</td><td>LDL-C rouptig)</td><td>iStatiy</td></tr><tr><td>4S 2009[42]</td><td>409</td><td>32.7</td><td>62.20</td><td>Simvastatin</td><td>20-40</td><td>5.5</td><td>CHD</td><td>54.75 mL/min/1.73 m²</td><td>6.85</td><td></td><td>M</td></tr><tr><td>Abe 2011[50]</td><td>104</td><td>43.3</td><td>64.70</td><td>Rosuvastatin</td><td>10</td><td>0.5</td><td>DN</td><td>69.85 mL/min/1.73 m²</td><td>5.83</td><td>39.4</td><td>M</td></tr><tr><td>AAPS 2010147</td><td>304</td><td>21.4</td><td>62.00</td><td>Lovastatin</td><td>20</td><td>4</td><td>HL</td><td>53 mL/min/1.73 m²</td><td>5.7</td><td>27</td><td>L</td></tr><tr><td>ALLHAT 2008[39]</td><td>7420</td><td>47.8</td><td>68.83</td><td>Pravastatin</td><td>40</td><td>4.8</td><td>HTN, DM</td><td>62.98 mL/min/1.73 m²</td><td>6.26</td><td>30.2</td><td>M</td></tr><tr><td>ALLIANCE 2009[43]</td><td>579</td><td>23.1</td><td>65.20</td><td>Atorvastatin</td><td>10-80</td><td>4.5</td><td>CHD</td><td>51.2 mL/min/1.73 m²</td><td>5.89</td><td>34.5</td><td>H</td></tr><tr><td>Bianchi 2003[31]</td><td>56</td><td>32.1</td><td>56.65</td><td>Atorvastatin</td><td>10-40</td><td>1</td><td>HTN</td><td>50.5 mL/min/1.73 m²</td><td>8.02</td><td>40.4</td><td>H</td></tr><tr><td>Buemi 2000[29]</td><td>21</td><td>38.1</td><td>37.00</td><td>Fluvastatin</td><td>40</td><td>0.5</td><td>GN</td><td>90 mL/min</td><td>5.12</td><td></td><td>L</td></tr><tr><td>CARDS 2009[41]</td><td>521</td><td>52.1</td><td>65.00</td><td>Atorvastatin</td><td>10</td><td>3.9</td><td>DN</td><td>63.42 mL/min/1.73 m²</td><td>5.42</td><td></td><td>M</td></tr><tr><td>ESPLANADE 2010[49]</td><td>186</td><td>24.2</td><td>51.40</td><td>Fluvastatin</td><td>40-80</td><td>0.5</td><td>DM</td><td>63.55 mL/min/1.73 m²</td><td>5.61</td><td>32.7</td><td>M</td></tr><tr><td>Fasset 2010[45]</td><td>49</td><td>61.2</td><td>51.00</td><td>Pravastatin</td><td>20</td><td>2</td><td>ADPKD</td><td>54.2 mL/min/1.73 m²</td><td>5.07</td><td>15.3</td><td>L</td></tr><tr><td>Goicoechea 2006[37]</td><td>63</td><td>36.5</td><td>68.10</td><td>Atorvastatin</td><td>20</td><td>0.5</td><td>DM,CVD</td><td>43.5 mL/min/1.73 m²</td><td>5.83</td><td>31.6</td><td>M</td></tr><tr><td>Hommel 1992[25]</td><td>21</td><td>42.9</td><td>38.00</td><td>Simvastatin</td><td>20</td><td>0.25</td><td>DM, Retinopathy</td><td>68 mL/min/1.73 m²</td><td>5</td><td>38.1</td><td>M</td></tr><tr><td>Imai 1999[28]</td><td>57</td><td>43.9</td><td>54.00</td><td>Pravastatin</td><td>5-10</td><td>0.5</td><td>DN, PKD, CGN, N</td><td>59.4 mL/min</td><td>6.49</td><td>19.4</td><td>L</td></tr><tr><td>JUPITER 2010[48]</td><td>3267</td><td>65.2</td><td>35.00</td><td>Rosuvastatin</td><td>20</td><td>2</td><td>CVD</td><td>56 mL/min/1.73 m²</td><td>4.89</td><td></td><td>H</td></tr><tr><td>Lee 2005[33]</td><td>82</td><td>0.32</td><td>49.00</td><td>Pravastatin</td><td>10</td><td>0.5</td><td>HTN</td><td>87.5 mL/min/1.73 m²</td><td>5.3</td><td>15.7</td><td>L</td></tr><tr><td>LORD 2010[46]</td><td>123</td><td>35.0</td><td>60.15</td><td>Atorvastatin</td><td>10</td><td>2.5</td><td>CKD</td><td>30.5 mL/min/1.73 m²</td><td>5.6</td><td>34.9</td><td>M</td></tr><tr><td>MEGA 2009[44]</td><td>7196</td><td>68.5</td><td>29.25</td><td>Pravastatin</td><td>10-20</td><td>5.3</td><td>CKD</td><td>62.65 mL/min/1.73 m²</td><td>6.3</td><td>18.9</td><td>L</td></tr><tr><td>Nakamura 2002[30]</td><td>40</td><td></td><td>20.40</td><td>Cerivastatin</td><td>0.15</td><td>0.5</td><td>IGA GN</td><td>103 mL/min</td><td></td><td></td><td>M</td></tr><tr><td>Nielsen1993[26]</td><td>18</td><td>33.3</td><td>65.00</td><td>Simvastatin</td><td>10-20</td><td>0.75</td><td>DM</td><td>96.85 mL/min/1.73 m²</td><td>5.5</td><td>34.1</td><td>M</td></tr><tr><td>Panichi2006[38]</td><td>55</td><td>20.0</td><td>57.50</td><td>Simvastatin</td><td>40</td><td>0.5</td><td>HTN</td><td>36 mL/min/1.73 m²</td><td>5.65</td><td>28.1</td><td>M</td></tr><tr><td>PREVEND-IT 2006[36]</td><td>788</td><td>34.3</td><td>51.50</td><td>Pravastatin</td><td>40</td><td>4</td><td></td><td>75.6 mL/min/1.73 m²</td><td>5.8</td><td></td><td>M</td></tr><tr><td>Sawara2008[40]</td><td>38</td><td>47.4</td><td>65.40</td><td>Rosuvastatin</td><td>2.5</td><td>1</td><td>MI,CHF</td><td>54 mL/min/1.73 m²</td><td>5.61</td><td>24.3</td><td>L</td></tr><tr><td>SHARP 2014[20]</td><td>6245</td><td>38.2</td><td>63.00</td><td>simvastatin</td><td>20</td><td>4.8</td><td>GN DN HTN</td><td>26.6 mL/min/1.73 m²</td><td>5.01</td><td>30.3</td><td>M</td></tr><tr><td>SPARCL 2014[51]</td><td>1600</td><td>57.9</td><td>68.00</td><td>atorvastatin</td><td>80</td><td>4.9</td><td>stroke,TIA</td><td>65.55 mL/min/1.73 m²</td><td>5.57</td><td>40.8</td><td>H</td></tr><tr><td>Thomas 1993[27]</td><td>30</td><td>40.0</td><td>50.50</td><td> simvastatin</td><td>10-40</td><td>0.5</td><td>NS</td><td>75.95 mL/min/1.73 m²</td><td>9.31</td><td>31.0</td><td>M</td></tr><tr><td>Verma 2005[35]</td><td>91</td><td>64.8</td><td>73.50</td><td>rosuvastatin</td><td>10</td><td>0.42</td><td>DM.HTN</td><td>45.85 mL/min/1.73 m²</td><td>5.79</td><td>42.9</td><td>M</td></tr><tr><td>WPISCOPS.CARE,</td><td>16245</td><td>10.6</td><td>60.40</td><td>pravastatin</td><td>40</td><td>5</td><td>CVD</td><td>63.23 mL/min/1.73 m²</td><td>5.74</td><td></td><td>M</td></tr><tr><td>Yasuda 2004[32]</td><td>80</td><td>53.8</td><td>57.50</td><td>fluvastatin</td><td>20</td><td>1</td><td>DM,CGN</td><td>59.5 mL/min/1.73 m²</td><td>6.2</td><td>25.0</td><td>L</td></tr></table></body></html>

Statlns Central RlskRatlo Rlsk Retlo   
Etudy or Subgroup EventsTotal_EvantsTotalWelghtM-H,Randem,55%CL -H.Random95% Cl   
ALLHAT 2008 503582 513738 3.0% 1.00 [0.68,1.47]   
LORD2010 458 7 65 0.3% 0.64 [0.20,2.08]   
SHARP 2014 10573116 10843129 9.6% 0.98 [0.91, 1.05]   
Total (5% C) 6856 932 100.0% 0.[0.01,1.05]   
Tot ovents 1111 1142   
Heergeney:Tau=000;ChP=0.51,df=2P=0.7y P=0% 0.01 01 7 10 100   
Test for overa eect: Z = 064 (P=0.52) Favou prmenaFavou oon Stal Centrol Risk Ratlo Fisk Ratlo   
udy rSbgrove EYen Tele Eyent Tolal Welght M-H.Randem.55%CL M-H.Rendom.95% CL   
JUPITER2010 31638 01629 23.0% 6.96 [0.36,134.67]   
SHARP 2014 3703110 4153129 77.0% 0.90 [0.79, 1.02]   
Totl 4T54 4758 100.0% 1.43 [0.26,7.79]   
Tota ovents 37 415   
Hoterogenoly: Tau²=0.9s;ChP=1.84, df=1[P=0.17): P=46% 0.01 01 1 10 10   
Tost for ovraeect:Z= 0.42 (P=0.68) Favours [orpermental]Fevours [oono St Centrol RikRatl RlskRatle   
Study or Subgmoup Evt Total Eents Tetal Weigt MHRdeP5CI MH.Random.95%CL 48200 5 专 13 210 0.% 0.41[0.15,1.12]   
AFCAPSTCAP82010 电 145 5 159 0.6% 1.32 [0.41, 4.22] LOAD2010 1 5 18 65 2.1% 0.81 [0.44, 1.50]   
WOSCOPS,CARE,UIPID 2005 7838181 6448004 96.5% 0.1 [0.83, 1.00] Total (95% cn 8583 8438100.0% 0.91[0.83,0.99] Totalevents 807 B   
P=% 5

![](images/1cce9d5c2888af44f98f077cd1c9b7850588df48d89e26fd62fd9a166268a149.jpg)  
Fig.2 Summary of risk of bias assessment.   
Fig.3Effects of statins compared withcontrolonprogression to ESRDin adults with CKD notrequiring dialysis therapy.   
Fig.4 Effects of statins compared with control on doubling of serum creatinine level in adults with $\mathsf { C K D }$ not requiring dialysis therapy.   
Fig.5Effects of statins compared with control on an eGFR reduction by over $2 5 \%$ in adults with CKD not requiring dialysis therapy.

Hyperlipidemia may play an important role in the progression of kidney diseasel4 e4,6.8]by exacerbating loss of kidney function and damaging the glomerular basement membrane[52].Statinsareknown tohavepleiotropic effects9 5s]andtheirenoprotectiveeffctsareprobably mediated by improving endothelial dysfunction [53] increasing renal perfusion [14] modulating inflammatory response to dyslipidemia [53]， andattenuatingcell apoptosis[9]

Previous studies that evaluated the effectsof

Stans Control Sed. Moan Dfnce Std. Mean Dtrence Study rSvbgrepMon 50TotL Mn 50 TatelWalght V.Randem5%CL IY.Rendem.95%Cl 1.1F SHARP2014 1.663913116-1.83 3.92 3129 24.6% 0.04 [-0.010.09] 日 Subtotal (95% Cn 3110 3129 24.0% 0.04[-0.01,0.0时] Heteregeney Not ppl Test rme5d Z=1.72P=00) 1..F ALLHAT 2008-1 -0.34 4,10 7 -0.02 446 77 6.1% 0.06[-0.03,0.1] ALLIANCE 2009 231 20 288 0.2 2 2 2.3% 0.00 [-0.07,0.25] Blnch 2003 -1 28 -58 0.18 2 0.2% 0,51 [-0.02, 1.05] ESPLANADE 2010 -3.742.18 92 -0.333.05 9 0.7% -0.09 [-0.38,0.20] Fasse 2010 -0.31 10.4 25 -1.34 12.2 1 0.2% 0.09 -0.53,0.71] Golcoechea 2006 -1.423.40 4 -1.324.52 19 0.2% -0.00 [-0.54,0.5] Imal 1999 -0.631.27 20 -4.630.33 1 0.2% 0.13 [-0.480.74] LORD2010 -1.043.84 58 -1.47 3.74 65 0.5% 0.11[-024,0.47] MEGA2009-1 33 7.13 1462 2.7 6.82 1518 11.7% 0.09[0.01,0.16] Panich2006 113.75 28 -213.53 2 0.2% 0.22[-0.31,0.75] Sw 2008 2.0 1 22 -22 17 1 0.1% 0.20 [-0.39,0. SPARCL201 4.2416.85 7 2.5317.09 1 0.3% 0.10 [0.00, 0.20] V 2005 4.81.1 4 21 141 心 0.4% 0.18 [-0.24,0.5] Yasoda 2004 -834.78 8 -033.88 4 0.3% -0.06[-0.50,0.3] Subtetal (p5% c) 3720 375 20.4% 0.09 [0.04, 0.13] Heteregoney:Teu²=o.00;ChP=5.39,df=13(P=0.g7)P=0% Testrve5t 2=367 (P-0.0002) 1ln GF Ab2011 0411.85 52 -0 9.76 5 0.4% 0.05 [-0.34,0.43] ALLHAT-2008-2 -1.13 4.31 2903 -1.18 4.35 2500 23.1% 0.01[-0.04,0.0] Bml2000 -5 51.9 1 -1337.12 1 0.1% 0.16 [-0,72 1.05] CARDS 2009 -2.0414.55 282 -247 13.3 259 2.1% 0.03[-014,0.20] Hommel1592 -1 2.5 12 2 23 中 0.1% -0.11[-0.970.76 Les 2005 13 19.7 42 41952 4 0.5% 0.45 [0.02, 0.89] MEGA2009-2 -2.610.31 2062 -2.610.01 2156 10.0% 0.00[-0.05,0.] Nakamra 2002 -2 10 20 2 12 20 0.2% -0.35[-0.98,0.27] ehn 1993 -06202 8 -5320.17 1 0.1% 0.36 [-0.58, 1.0] PREVENDHT 2005 0.619.42 400 -1 121 388 3.1% 0.10 [-0.04,0.24] Th1993 -4.1 25 7 -15.7 2 1 0.1% 0.53[-0.45,1.51] Subtoal (95% Cl) 5781 6912 45.0% 0.02[0.02,0.05] Hoeregeny: Tau=.0o;ChP=8e1, df=10 (P =D.5）；P=0% Tesrvet Z=04 （P=0.35) Tol (95% Cp 12523 12808100.0% 0.04 [0.02, 0.07] Heterogeney Taua=0.00:ChP=19.20,df=25(P=0.7g):I=0% Test rovll5ct Z=3.8(P=0.0005) F Tast for subrouo droe:ChP =5.20, cf=2 rP=0.07 i\*=61,6%

statins on progression of CKD yielded inconsistent results.Some studies reported benefits of statins on slowing down GFR reduction[31, 42.51l，while some others did not show any benefits to the renal outcomes[20.45,47]. The first meta-analysis of 13 studies by Fried et al [54. found a modest improvement of kidney function in patients receiving statin therapy,but this finding did not seem convincing given the small number of studies and participants included,short duration of observation and poor study quality.In another meta-analysis of 27 randomized trials, Sandhu et al [16] found that statin therapy modestly slowed down the rate of kidney function loss by $1 . 2 2 \mathrm { \ m L / m i n }$ per year,but apart from the substantial heterogeneity of the studies included, they failed to provide the clinically relevant outcome of interest: progression of CKD to ESRD.The findings of a Cochrane systematic review have indicated that statins haveuncertain effectsonprogression of kidney disease [19].Inthismeta-analysis,westudiedthe clinicallyrelevant outcomes and found thatstatin therapy had little or no effect on doubling of serum creatinine levels or progression of CKD to ESRD.We also studied the effects of statins on eGFR reduction by over $2 5 \%$ and found that statin therapy may be beneficial to improve GFR in CKD patients.

Based on the overall pooled data from 24 studies of $2 5 ~ 4 2 9$ participants,we found beneficial effects of statin therapy on eGFR changes in CKD patients.A subgroup analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study suggested that the effect of statin therapy issubjected to influences by baseline eGFR and pravastatin may prove beneficial on renal function in patients with moderate CKD [44]. In our meta-analysis, we took baseline eGFR into consideration and found that statin treatment did not significantly reduce kidney function loss in patients with mild or severe CKD,but showed a significant beneficial effect in the much larger subgroup of moderate CKD,suggesting the potential benefit of statins for patients with moderate CKD.To evaluate the drug-specific effects on renal function,we conducted a subgroup analysis by statin types and found that only atorvastatin produced a beneficial effect on eGFR changes,which was consistent with the finding in

Centrel S1d.n Dc n Die Studyor Subgroup W SToM SDTote Weght N.Rom Y. 1.515in Homel 1992 -1 25 12 2 2 9 1% -0.11[-0.97,0.7] Neln 1890 点 202 中 2017 1 1% 0.6 [-0.58, 1.] Penlch 2006 113.75 2 -213.53 2 .2% 0.22[-0.31,.75] SHARP2014 -1. 31 3118-1.83 32 312 24.% 0.04-0.01, 中 Th1 41 25 1 -157 21 10 01% 0.53[-0.45,1.5] 8ubot (55% t) 3171 3185 25.0% 0.05[-0.000 + Hategny:Ta0.00;Cs=1.8a,df=4[P=0.76)P0% Ter o t 2=1.5 P=0.06) 1.5.2 Aon ALLIANCE2009 2.31 25 20 0.2 22 2 2.3% 0.09 [-0.07, 0.25] Blndh2003 1 9.27 2 -58 9.18 28 0.2% 0.51[-0.02,1.05] CARDS 2009 2041458 22-247 1 2 2.1% 0.03 [-0.14, 0.20] Gococha 2000 -1.423.45 4 -1324.82 1 0.2% -0.00 [-0.54,0.] LORD201 1.043.84 5-147 3.74 电 .5% 0.11[-0.24,0.47] SPAACL2014 4.4216.5 7 2.5317.00 0.11[0.01,02] ubotl (55% C) 147 1475 11.5% 0.10 [0., 0.17 Heoeney:T=0.;CsP=3.15,df=5P=.8eP=0% Tetr  t Z=265 P=0.00） 1.5.3 Patln ALLHAT 2008-1 -4 L m -2 m 41% .0-0.03,1] ALLHAT-2008-2 -1 431 2903-1.18 4.35 2900 23.1% 0.01[-0.04,.] F2010 -0.31 104 5 -1.34 122 1 0.2% 0.09[-0.53,0.71] 0631.27 2 4630.33 1 0.2% 0.13 [-0.48,0.74] Lee2005 1 17 42 1 15 40 0.3% 0.45[0.02,0. MEOA2009-1 出 7 1 2 8.82 1510 11.7% 0.09 [0.01,0.1 MEOA2001-2 281031 2062 2810.01 2150 1.6% 0.00 [-0.06, 0.0] PREVENDHT2000 61942 400 1 121 3 31% 0.10 [-0.04,0.2] ubC 7 7872 1.3% 0.04[0.000.08] HeroeyT=0.00;CP=8.,df=7P=0.2 P=20% Testor oveallctZ=2.(P=0.04) 14Fn B 2000 13 -1327.12 1 1% 0.16[-0.72,1.] ESPLANADE2010 3.742.18 2 3305 H 0.7% -0.00 [-0.38,0.20] Yasda 2004 3 1 0.3% -0.06 [-0.50,0. u 14 143 11% -006[-0.2,07] Hseogey:Ta=0.00;CP=0.2,df=2P=0. P=0% Tet or ovl et Z=0. P=0.0) 155Rosn Ab2011 -411.5 5 9.7 5 4% .05[-0.34, S200 2 14 2 22 17 1 0.1% 0.26[-0.39,. V2005 4 18.1 4 21 14.1 4 .4% 0.18[-0.24,0.5 Subo 2 1 0.13[-0.13,0.时 Hetegny:Taa=0.00;C²=0.38,df=2[P=0.83]P=0% Testr ovlet Z=0.s（P=0.32） 1Ce 2002 + 1 2 2 12 2 -0.35[-0.98,0.27] Subot (5% C) 2 2 0.2% 0.35[-0.88,0.27] Hgy Hot Tt r e 21.11 027 T 1 1204 100.0% 0.04 [0.02,0.07] F H:T= 0.0;CP=19.73,=25P=0.7:P=% 1 -5 0 品 1 Tetr eet Z=3.4 P=0.0004) Fu [qeea]Fvou oo] Test r enoeCP-4df=5iP =0L P=%

a previous meta-analysis[18].The effects of statin therapy on kidney function are associated with statin doses. According to Sanguankeo et al [5], a high-intensity statin therapy was associated with improved kidney function, which was consistent with our findings in subgroup analysis that high-intensity statin therapy produced a significant beneficial effect on eGFR changes as compared with moderate-andlow-intensitystatin therapies. Compared with the study by Sanguankeo et al [5s]， we included more RCTs with large sample sizes without substantial heterogeneity among the studies. Our results demonstrate that reduced LDL-C levels are significantly associated with eGFR changes and suggest a probable dose-response effect of statins in CKD patients.

We noted that the outcomes of ESRD events and doubling of serum creatinine level were inconsistent withtheoutcomesofkidneyfunctions.This inconsistency might arise from the difference in the studies included in the analysis,as we analyzed 24 studies for the effects of statins on eGFR changes,but only3 studies and 2 studies were available that examined the effects of statins on progression of CKD to ESRDand on doubling ofserum creatinine level, respectively.The difference in clinical characteristics of thestudyparticipantsacrosstheanalysesalso contribute to the inconsistency in the outcomes.For

St Centrol d n D tdMean Dene Mn 80 TotLMeen HD Teg N.Rndo% W.Rn 1.151igy ALLIANCIE 2009 21 25 2 02 3 2 23% 0.09[-0.07,0.25] Bianchi 2003 1 27 -5 9.18 28 0.2% 0.51[-0.02,1.05] SHARP2014 4.4218.85 789 25317.0 H 6.% 0.11[001,21 bta p% CI) 110 112 U 012 [0.02,.21 Htegenay:Tu²=0.00;ChP=2.25,df=2(P=0.32）;F=11% T lor o 2=240=0.02 1.15.2Modertebenslty apy Ab2011 -0411.5 5 自 9.70 5 04% 0.05 [-0.04 ALLHAT2008-1 -034 41 9 -0.82 4.48 T 6.1% 0.06[-0.03,0.16] ALLHAT-2008-2 -1.13 431 2-1.18 4.35 20 23.1% 0.011-0.04,0.0 CARDS 2009 -2.041458 3 -247 1 259 2.1% 0.03[-014,0.20 ESPLANADE2010 -3742.18 8 333.55 H 0.7% -0.09[-0.38,0.20] Golcoechea 2006 -1.423.45 4 -1.324.52 中 0.2% -0.00[-0.54,0.53] Hmml12 -1 35 12 2 2 + 0.1% -0.11[-0.97,0.7] LORD2010 -1.04 3.84 58-1.47 3.74 65 0.5% 0.11 [-0.24,0.47] Nakamura 2002 4 1 2 2 1 2 02 -0.35(-0.94,0.27] Ns1 -0. 20.2 喜 -6320.17 1 0.1% 0.36[-0.58,1.30] Panichi 2006 11375 2 -213.53 2 0.2% 0.22|-0.31,075 PREVENOHIT 2000 0 1942 400 =1 12.1 3 3.1% 0.10 [-0.04,0.24] SHARP2014 -1.68 3.91 3118-1.53 3.52 312 24.0% 0.04 [-0.01,0.09] Thomas1 1 2 7-17 出 1 0.1% 0.50 [-0.4,1.51] Va 2006 山 161 48 21 1L1 4 0.4% 018-0.24,0. uttal 5% C T829 73 81.7% 0.04 [0.00,007] HegenyT/a=0.00;ChP=9,df=14（P=094P=0% Tetorvct2=2.24（P=0.03） 1.15.3Low ntaythey Buemi 2000 -5 51. 1 -1337.12 1 01% 0.18 [-0.72,1.05] Fasse 2010 -021 10.4 25-1.34 12 1 0.2% 0.09-0.53,7 1999 -031.27 2 630.33 1 0.2% 0.13 [-045,0.74] Lee2005 1 197 42 419.52 4 0.3% 0.450020.8 MEGA 2009-1 出 7.1 142 2 电 11.7% 0.09[0.01.0.15 MEGA2009-2 -2 10.31 2062 -2.610.01 2158 16.6% 0.00[-0.06,0.05] Sar 2008 2 194 2 2 18 体 01% 0.20 |-0.3,0. Ya 2004 3 39 4 4 0.3% -0.06 [0.50,0.38 C 381 20.5% 005[-01,1 Hseogeney Tu=0.0oChP=7.g,d=7(P=0.a: P=0% Testor vet 2=1.6(P=0.10) Total [5% Cq 11% .4[0 中 Hegeney:Teu²=0.00;ChP=19.72，d=25P=0.76）P=0% 1 T lor ovect 2=3.54 P=0.0004) 1 点5 中 05 Faus lpertaFavous oota Te or sbrou drosChF=251df=2P=02 P=20.3%

instance,the mean baseline eGFR was $2 6 . 6 \mathrm { \ m L } / \mathrm { m i n } /$ $1 . 7 3 \mathrm { m } ^ { 2 }$ in the SHARPstudy 20]as compared to $3 0 . 5 \mathrm { m L / m i n / }$ $1 . 7 3 ~ \mathrm { m } ^ { 2 }$ in the LORD study [46]. In the SHARP study, the high proportion $( 6 3 \% )$ of non-dialysis patients with stage 4 or 5 CKD at randomization possibly diminished the beneficial effects of statin therapy on progression of CKD to ESRD.The differences across the studies in statin types used, the intensity of statin therapy,and the duration of patient follow-up are all factors that may influence the overall effects of statins on the progression of CKD.The LORD study,for instance,found that the decline in GFR was lessened during the first 2 years and at the end of the follow-up period,and no significant differences were found between the statin and placebo groups[46]

There were some limitations in our analysis.First, we included post-hoc analyses of CKD subgroups from RCTs not specifically designed to assess patients with CKD,which may have introduced bias;Second, few of the included studies directly addressed the effects of statins on renal outcomes in CKD patients; Third,the measurement of kidney function differed among some RCTs；Fourth, although therewasno substantial heterogeneity in this study,we should not ignore the differences among the RCTs,especially the clinical heterogeneity；Lastly,in some studies，patientsalso received concomitant therapy,which may introduce bias to our results.

# Conclusion

Although statins may not prevent the progression of CKD to ESRD and the doubling of the serum creatinine level, they appear to improve GFR or reduce the decline in GFR in CKD patients.These effects of statins are probably associated with the patients'baseline eGFR level,statin types used,and the intensity of statin therapyreceived.

# REFERENCES

[1]Maneesh S,Navdeep T,Melania P,et al. Risk of end-stage renal disease _and death after cardiovascular events in chronic kidney disease [J]. Circulation,2014,130(6): 458-65.   
[2]Gansevoort RT,Correa-Rotter R,Hemmelgarn BR,et al. Chronic kidney disease and cardiovascular risk:epidemiology,mechanisms, and prevention [J].Lancet, 2013,382(9889): 339-52.   
[3]Braun L,Sood V,Hogue S,et al.High burden and unmet patient needs in chronic_kidney disease[J]. Int JNephrol RenovascDis, 2012, 5(5): 151-63.   
[4]Iseki K.Epidemiology of dyslipidemia in chronic kidney disease[J]. Clin Exp Nephrol,2014,18(2): 185-8.   
[5]UpadhyayA.Statinsin_chronickidneydisease:whatdometaanalyses tellus[J]?ClinExp Nephrol,2014,18(2):278-81.   
[6] Chen S,Hung C,Kuo M,et al.Association of dyslipidemia with renal outcomes in chronic kidney disease [J]. PLoS One,2013,8(2): e55643.   
[7]Gluba A,Rysz J,Banach M. Statins in patients with chronic kidney disease: why,who and when ［J]? Expert Opin Pharmacother,2010, 11(16): 2665-74.   
[8]Liu ZS,Liu DW.Dyslipidemia promotestheprogressionof chronic kidney disease [J].Chin JMed (Engl),2013,126(7):1203-6.   
[9] Nam HK,Lee SJ,KimMH,et al.Rosuvastatin attenuates inflammation,apoptosis_and fibrosis inarat model of cyclosporineinduced nephropathy [J].Am JNephrol,2013,37(1): 7-15.   
[10] Yen C, Sun C, Leu S,et al. Continuing exposure to low-dose nonylphenol aggravatesadenine-induced chronic renal dysfunction and roleof rosuvastatin therapy[J].JTransl Med,2O12,10(1):147.   
[11]Hamasaki Y,Doi K,Okamoto K,etal.3-Hydroxy-3- me- thylglutarylcoenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway [J].Lab Invest,2012,92(8): 1161-70.   
[12] Sonmez A,Yilmaz MI,Korkmaz A,et al. Hyperbaricoxygen treatmentaugmentstheefficacy of cilazapril and_simvastatin regimens in an experimental nephrotic syndrome model[J]. Clin Exp Nephrol,2008,12(2): 110-8.   
[13]de Barros EP,Garcia-Pinto AB,Machado PY,et al. Rosuvastatin beneficially alters theglomerularstructure kidneysfrom spontaneously hypertensive rats (SHRs)[J].J Mol Histol,2011,42 (4): 323-31.   
[14] Kamdar C,Chou S,Mooppan UMM,et al.Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction [J]. Urology,2010,75(4): 853-7.   
[15]Giunti S,Calkin AC,Forbes JM, et al.The_pleiotropic_actions of rosuvastatin conferrenal benefits inthe diabetic Apo-E knockout mouse[J].Am JPhysiol Renal Physiol,2010,299(3): F528-35.   
[16]Sabrina S,Natasha W,FriedLF,etal.Statins for improvingrenal outcomes:a meta-analysis [J].J Am Soc Nephrol,2006,17(7): 2006-16.   
[17]Nikolic D, Banach M,Nikfar S,et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important [J]? Int J Cardiol,2013,168(6): 5437-47.   
[18] Takagi H,Umemoto T.A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease [J]. Int J Cardiol,2011,152(2): 242-4   
[19]Navanethan SD,Pansini F,Perkovic V,et al. HMG CoA reductase inhibitors(statins)for people withchronickidney disease not requiring dialysis[J]. Cochrane Database Syst Rev,2009,5(2): D7784.   
[20] Richard H,David L,Jonathan E,et al.Effects of lowering LDL cholesterol on progression of kidney disease [J].JAm Soc Nephrol, 2014,25(8): 1825-33.   
[21]LeveyAS,Coresh J,Balk E,etal.National KidneyFoundation practiceguidelinesforchronickidneydisease: evaluation, classification,and stratification[J].Ann Intern Med,2003,139(2): 137-47.   
22]Higgins JPGreenS(editors).CochraneHanboofrSystetic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration,2011．[Available at www.cochranehandbook.org]   
[23]Higgins JPT,Thompson SG,Deeks JJ,et al. Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414): 557-60.   
[24]Ray KK,Kastelen JP,S Matthijs B,et al. The ACC/AHA 2013 guidelineonthetreatmentofbloodcholesteroltoreduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain:a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011[J]. Eur Heart J,2014,35(15): 960-8.   
[25]Hommel E,Andersen P,GallMA,et al.Plasma lipoproteinsand renal function during simvastatin treatment in diabetic nephropathy [J].Diabetologia,1992,35(5): 447-51.   
[26]Nielsen S,Schmitz O,MpllerN,etal.Renal functionand insulin sensitivity during simvastatin treatment in type (non-insulin-dependent) diabetic patients with microalbuminuria [J]. Diabetologia,1993,36(10): 1079-86.   
[27]ThomasME,HsKPRamswamyCetal.Simastatiayfor hypercholesterolemic patients with nephrotic syndrome or significant proteinuria[J]. Kidney Int,1993,44(5): 1124-9.   
[28] Imai Y,Suzuki H, Saito T,et al.The efect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and_hyperlipidemia. Pravastatin and Renal Function Research Group[J]. Clin Exp Hypertens,1999,21(8): 1345-55.   
[29]BuemiM,AllegraA,Corica F,etal.Effectof fluvastatin_on proteinuria in patients with immunoglobulin A nephropathy [J].Clin Pharmacol Ther,2000,67(4): 427-31.   
[30]Nakamura T,Ushiyama C,Hirokawa K,et al.Eect of cerivastatin onproteinuriaand_urinary podocytesin patientswith chronic glomerulonephritis[J].Nephrol Dial Transplant,2002,17(5): 798-802.   
[31]Bianchi S,gaiR,Czza A,etal.Aotrolled,prospciedy of the effectsof atorvastatinonproteinuriaand progressionof kidney disease[J].Am JKidney Dis,2003,41(3): 565-70.   
[32]YasudaGKujiTHasegawaK,etal.Safetyandefficacof fluvastatin in hyperlipidemic patients with chronic renal disease [J]. Ren Fail,2004,26(4): 411-8.   
[33]Lee T,Lin M,Tsai C,et al.Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptorblockers[J].KidneyInt,2005,68(2): 779-87.   
[34]TonellissCanetofsaitefd function loss inpeople with or at risk forcoronary disease[J]. Circulation,2005,112(2): 171-8.   
[35] Verma A,Ranganna KM,Reddy RS,et al.Efect of rosuvastatinon C-reactive protein and renal function in patients with chronic kidney disease[J].AmJCardiol,2005,96(9): 1290-2.   
[36]Atthobari J,Brantsma AH,GansevoortRT,etal.The eectofstatins on urinary albumin excretionand glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study[J].Nephrol Dial Transplant,2006,21(11): 3106-14.   
[37]Marian G,Soledad Garcia DV,Vicente L,et al.Effects of atorvastatin oninflammatoryand fibrinolyticparametersinpatientswith chronic kidney disease [J].JAm Soc Nephrol,2006,17(12Suppl3): S231-5.   
[38]Panichi V,Paoleti S,MantuanoE,etal.In vioand invitro effects of simvastatin oninflammatorymarkersin pre-dialysispatients [J]. Nephrol Dial Transplant,2006,21(2): 337-44.   
[39]Rahman M,Baimbridge C, DavisBR,et al.Progressionof idney disease in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin versus usual care:a report from the AntihypertensiveandLipid-Lowering Treatmentto Prevent Heart Attack Trial (ALLHAT)[J].AmJKidney Dis,2008,52(3): 412-24.   
[40]SawaraY,Takei T,Uchida K,etal.Effectsoflipid-loweringteapy with rosuvastatin_on atherosclerotic burden in_patientswith chronic kidney disease[J].Intern Med,2008,47(17): 1505-10.   
[41] Colhoun HM,Betteridge DJ,Durrington PN,etal.Effectsof atorvastatinon kidney outcomes and cardiovascular disease in patientswithdiabetes:ananalysis from the Collaborative Atorvastatin Diabetes Study(CARDS)[J].Am JKidney Dis,2009,54 (5): 810-9.   
[42]HuskeyJ,LindenfeldJ,Cook T,etal.Effctofsimvastatinon kidney functionlossinpatientswithcoronaryheartdisease[J]. Atherosclerosis,2009,205(1):202-6.   
[43]Koren MJ,Davidson MH,Wilson DJ,etal.Focused atorvastatin therapy_in managed-care patients with coronary heart disease and CKD[J].Am JKidney Dis,2009,53(5): 741-50.   
[44]NakamuraH,MizunoK,Ohashi Y,etal.Pravastatinand cardiovascularriskinmoderatechronickidneydisease[J]. Atherosclerosis,2009,206(2): 512-7.   
[45]Fassett RG, Coombes JS,Packham D,et al.Effect of pravastatinon kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease [J]. Scand J Urol Nephrol,2009,44(1): 56-61.   
[46]Fassett RG,Robertson IK,Ball MJ,et al. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised doubleblind placebo-controled trial[J].Atherosclerosis,2010,213(1): 218-24.   
[47]Kendrick J,Shlipak MG,Targher G,etal.Effectof lovastatinon primary prevention of cardiovascular events in mild ckd and kidney functionloss:apost hocanalysisof theAir Force/Texas Coronary Atherosclerosis Prevention Study[J].AmJKidney Dis,2010,55(1): 42-9.   
[48]Ridker PM,MacfadyenJ,CressmanM,etal.Effcacyofrosuvastatin among men and women with moderate chronic kidnev disease and elevated high-sensitivity C-Reactive protein [J].J Am Coll Cardiol, 2010,55(12): 1266-73.   
[49]Ruggenenti P,Perna A,Tonelli M,et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial[J]. Clin J Am Soc Nephrol,2010,5(11): 1928-38.   
[50]Abe M,Maruyama N,Okada K,et al.Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy[J].JAtheroscler Thromb,2011, 18(11): 1018-28.   
[51]Pierre A,Alfred C,Campese VM,et al．Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial [J]. Stroke,2014,45(10): 2974-82.   
[52]Moorhead JF.Lipids and progressive kidney disease [J].Kidney Int Suppl,1991,31(4): S35-40.   
[53]Fiore MC,Jimenez PM,Cremonezzi D,et al. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake[J].Am JPhysiol Renal Physiol,2011,301(2): F263-70.   
[54]Fried LF,Orchard TJ,Kasiske BL.Effect of lipid reduction on the progression of renal disease: a meta-analysis [J].Kidney Int, 2OO1,59 (1): 260-9.   
[55] Sanguankeo A, Upala S,Cheungpasitporn W,et al. Effects of statins on renal outcome in chronic kidney disease patients:a systematic review and meta-analysis [J].PLoS One,2015,10(7): e132970.

# 他汀类药物治疗对延缓慢性肾脏病进展的荟萃分析

刘宗瑞'，赵 豪1，陈艳荣²,唐冬冬',牛红心1  
南方医科大学珠江医院'肾内科，急诊科，广东广州510280

摘要：目的 评价他汀类药物治疗对非透析的慢性肾脏病患者肾脏病进展的影响。方法 通过对电子数据库(时间截止2015年2月)的检索，筛选符合纳人标准的随机对照试验，采用随机效应模型合并相关肾脏病进展指标。结果共纳入28个研究，共包括45 688例慢性肾脏病患者。Meta分析结果显示，与对照组相比，非透析的慢性肾脏病患者接受他汀类药物治疗不能减少终末期肾病的发生（ $\mathrm { R R } { = } 0 . 9 8 , 9 5 \%$ CI:0.91-1.05)，也不能降低肌酐翻倍风险(RR $1 . 4 3 , 9 5 \%$ CI0.26to7.79)，但是可以降低肾小球滤过率下降 ${ \geq } 2 5 \%$ 的风险 $\mathrm { R R = 0 . 9 1 , 9 5 \% }$ CI $: 0 . 8 3 { = } 0 . 9 9$ 以及延缓肾小球滤过率下降 $\mathrm { ( S M D { = } 0 . 0 4 , 9 5 \% }$ CI:0.02-0.07)。亚组分析显示,在中度慢性肾脏病患者中，他汀类药物治疗对治疗前后肾小球滤过率变化这一指标有疗效 $\operatorname { S M D = } 0 . 0 9 , 9 5 \%$ CI: $0 . 0 4 =$ 0.13)。阿托伐他汀( $_ { \mathrm { S M D = 0 . 1 0 , 9 5 \% } }$ CI:0.03-0.17)及高强度降脂治疗( $\operatorname { S M D = 0 } . 1 2 , 9 5 \%$ CI:0.02-0.21)对治疗前后肾小球滤过率变化这一指标有效。结论尽管他汀类药物对降低终末期肾病发及肌酐翻倍的发生率无明显效果，但可以延缓肾小球滤过率下降,其疗效与肾脏病分期、药物种类及降脂强度有关。

关键词：他汀类药物;慢性肾脏病;终末期肾病；肾小球滤过率；荟萃分析

收稿日期：2015-12-22  
基金项目：国家自然科学基金(81170682)  
作者简介:刘宗瑞,硕士研究生,E-mail: liuzongruihao@126.com  
通信作者：牛红心,医学博士,教授,硕士生导师,电话:020-61643888,E-mail:nhongxin $@$ 126.com